Stock markets in India are presently trading on a flat note. The BSE Sensex is trading down by 41 points and the NSE Nifty is trading up by 7 points. The BSE Mid Cap index is trading up by 0.4%, while the BSE Small-Cap index are trading down by 0.1%.

Among the sectoral indices, FMCG stocks and bank stocks are witnessing maximum selling pressure. Metal stocks and oil & gas stocks are trading in green.

If you look at the stock market returns over the years, you will see that the markets have never moved in a linear fashion.

It has never been a one-way street - only up or down.

Stock markets have always moved in cycles.

If you would have bought stocks when either the Sensex or the Smallcap index was in a downturn, you would have made big returns once the cycle turned and the bulls took over.

The Time to Buy Stocks is Now

The economic slowdown does not herald the end of the world or for that matter the end of India. It's a phase and like all phases - This too shall pass.

The real question is - Are you taking advantage of these price declines to buy quality stocks?

In the news from the aviation sector. Directorate General of Civil Aviation (DGCA) in its monthly data has showed that India's domestic air passenger traffic rose by 3% in July over the year-ago period, with local carriers flying 11.9 million passengers in the month.

Domestic airlines flew 11.6 million passengers in the same month last year. In June 2019, the country's domestic air passenger traffic rose 6.2% compared to the year-ago period.

In terms of market share, country's largest carrier, IndiGo maintained its lead position with 47.8% share of the domestic passenger market in July. SpiceJet's market share fell from 15.6% in April to 15.5% in July, giving it the number two spot.

The market share of Air India, GoAir, AirAsia and Vistara were 14.8%, 13.3%, 7.7%, and 7.2%, respectively, in July this year.

According to the data, the passenger load factor of all the major airlines declined in July as compared to June 2019, due to the end of the tourist season.

Besides, Air India topped the list of passenger grievances with 2.1 complaints per 10,000 passengers in the month of July, while SpiceJet was on number two position with 0.8 complaints per 10,000 passengers.

Moving on to the news from the pharma sector. As per an article in a leading financial daily, Biotechnology major Biocon's Malaysian arm has received the European Union Good manufacturing practice (EU GMP) certification for its insulin facility in Malaysia.

Reportedly, the insulin facility in Malaysia manufactures drug substance and drug products in vials, cartridges, and insulin delivery devices was inspected in May 2019.

The company's range of insulins made at the facility is serving patient populations in the EU and several other countries across the globe. Biocon's rh-Insulin is registered in over 40 countries worldwide and has been commercialized in many emerging markets.

The company's biosimilar Insulin Glargine has been approved in over 60 countries and is commercialized in several key emerging markets, the reports noted.

Speaking of the biosimilars, note that, Biosimilars and Biologics are burgeoning sectors. Also, major scientific and technological advances, coupled with socio-demographic changes and increasing demand for medicines will revive the pharma industry's fortunes in another 10 to 20 years.

But given the complexity of biologics, will Indian companies be able to break some ground in this space? Going forward, whether the monetization of biosimilars prove to be a big growth driver for the company will be the key thing to watch out for.

Biocon share price was trading down by 1.1% at the time of writing.